Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-59865-1
Affiliations:
10
Authors:
26
Go to article
Institutions Authors Share
Dongguan People's Hospital, China
17.500000
17.500000
 0.67
The Fifth Affiliated Hospital, SYSU, China
5.000000
 0.19
Southern Medical University (SMU), China
2.000000
 0.08
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
 0.04
Jinan University (JNU), China
0.500000
 0.02
Interested in Oncology and Carcinogenesis?